Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2).
Liu, Q., Batt, D.G., Lippy, J.S., Surti, N., Tebben, A.J., Muckelbauer, J.K., Chen, L., An, Y., Chang, C., Pokross, M., Yang, Z., Wang, H., Burke, J.R., Carter, P.H., Tino, J.A.(2015) Bioorg Med Chem Lett 25: 4265-4269
- PubMed: 26320619 
- DOI: https://doi.org/10.1016/j.bmcl.2015.07.102
- Primary Citation of Related Structures:  
5BPY, 5BQ0 - PubMed Abstract: 
Four series of disubstituted carbazole-1-carboxamides were designed and synthesised as inhibitors of Bruton's tyrosine kinase (BTK). 4,7- and 4,6-disubstituted carbazole-1-carboxamides were potent and selective inhibitors of BTK, while 3,7- and 3,6-disubstituted carbazole-1-carboxamides were potent and selective inhibitors of Janus kinase 2 (JAK2).
Organizational Affiliation: 
Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 4000, Princeton, NJ 08543-4000, USA. Electronic address: [email protected].